logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

GlycoMimetics: A Lot to Tell at the ASCO Meeting

GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most advanced drug, rivipansel, a pan-selectin antagonist , is being developed for vaso-occlusive crisis in sickle cell disease. The product is in a Phase 3...

Read More

May 25, 2017

0

Exelixis: The European Commission approves Cabometix for first line treatment of poor-risk advanced renal cell carcinoma

Exelixis (EXEL)  announced that its partner Ipsen received approval from the European Commission (EC) for  CABOMETYX ® (cabozantinib) 20 mg, 40 mg and 60 mg   for the first-line treatment of adults with intermediate or poor-risk advanced renal cell carcinoma (RCC) in the European Union....

Read More

May 17, 2018

0

An FDA Advisory Committee Voted in Favor of Approving Akcea Therapeutics’ Product, WAYLIVRA, for FCS Syndrome.

Ionis Pharmaceuticals (IONS)  and   Akcea Therapeutics (AKCA) ,  an affiliate of Ionis Pharmaceuticals, announced that the Advisory Committee of the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products voted 12-8 in support of approving the firms’ product ...

Read More

May 14, 2018

0

Celgene has important CAR T presentations at ASH

At the 60th American Society of Hematology (ASH)  Annual Meeting    CAR T is Still a Star With all the pessimistic views critics have sprayed around in the past few years about the cell therapy for cancer, the CAR T...

Read More

December 4, 2018

0

CARA Therapeutics has good news

Cara Therapeutics (CARA)  develops novel and proprietary class of product candidates, led by  Korsuva  (CR845/difelikefalin) injection. This product is a first-in-class peripheral kappa opioid receptor (KOR) agonist designed to alleviate pruritus (itching) and pain.   In Phase 2 trials,  Korsuva injection...

Read More

May 23, 2018

0

Exelixis initiates a phase 3 trial with cabozantinib combination for previously untreated liver cancer

Exelixis (EXEL) and  Ipsen (Euronext: IPN; ADR: IPSEY)   announced the initiation of COSMIC-312. A phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (T ECENTRIQ ® ) versus sorafenib, in previously untreated advanced hepatocellular carcinoma ( H...

Read More

December 6, 2018

0

AstraZeneca and Genentech Checkpoint Inhibitors improve survival in two different Lung Cancers

ASTRAZENECA AstraZeneca’s (AZN) Checkpoint Inhibitor Imfinzi significantly improved Overall Survival (OS) for  Stage III Non-Small Cell Cancer Imfinzi  (durvalumab) achieved positive overall survival (OS) results for the Phase III PACIFIC trial in patients with unresectable Stage III non-small cell lung...

Read More

May 29, 2018

0

Amgen: The FDA approves Aimovig™. The first specific migraine drug

The U.S. Food and Drug Administration (FDA) approved  Amgen’s (AMGN)  new once a month drug Aimovig™ (erenumab-aooe) for the prevention and treatment of migraine in adults. Aimovig is the first and only FDA-approved treatment specifically developed to prevent migraine. The drug blocks calcitonin gene-related peptide...

Read More

May 18, 2018

0

The FDA Approves Keytruda for primary Mediastinal Large B-Cell Lymphoma (PMBCL)

–  Keytruda becomes the first anti-PD-1 therapy to be approved for PMBCL   – This is the 2nd indication for Keytruda for a hematologic malignancy. – The approval is based on tumor response rate and durability of response. The FDA...

Read More

June 14, 2018

0

A follow up on Gilead's latest news

The Chinese National Medical Products Administration  (NMPA) has approved Gilead’s (GILD) HIV combination product Descovy ®.  In China, Descovy is to be indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) in adults and...

Read More

December 12, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 50
  • 51
  • 52
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy